© 2000 American Heart Association, Inc.
Integrative Physiology |
The Antianginal Drug Trimetazidine Shifts Cardiac Energy Metabolism From Fatty Acid Oxidation to Glucose Oxidation by Inhibiting Mitochondrial Long-Chain 3-Ketoacyl Coenzyme A Thiolase
From the Cardiovascular Research Group and the Division of Pediatric Cardiology (P.F.K., R.K., G.D.L.), University of Alberta, Edmonton, Canada, and Institut De Recherches Internationales Servier (A.L.), Courbevoie, France.
Correspondence to Gary D. Lopaschuk, 423 Heritage Medical Research Center, University of Alberta, Edmonton, Canada, T6G 2S2. E-mail gary.lopaschuk{at}ualberta.ca
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Abstract—Trimetazidine is a clinically effective antianginal agent that has no negative inotropic or vasodilator properties. Although it is thought to have direct cytoprotective actions on the myocardium, the mechanism(s) by which this occurs is as yet undefined. In this study, we determined what effects trimetazidine has on both fatty acid and glucose metabolism in isolated working rat hearts and on the activities of various enzymes involved in fatty acid oxidation. Hearts were perfused with Krebs-Henseleit solution containing 100 µU/mL insulin, 3% albumin, 5 mmol/L glucose, and fatty acids of different chain lengths. Both glucose and fatty acids were appropriately radiolabeled with either 3H or 14C for measurement of glycolysis, glucose oxidation, and fatty acid oxidation. Trimetazidine had no effect on myocardial oxygen consumption or cardiac work under any aerobic perfusion condition used. In hearts perfused with 5 mmol/L glucose and 0.4 mmol/L palmitate, trimetazidine decreased the rate of palmitate oxidation from 488±24 to 408±15 nmol · g dry weight-1 · minute-1 (P<0.05), whereas it increased rates of glucose oxidation from 1889±119 to 2378±166 nmol · g dry weight-1 · minute-1 (P<0.05). In hearts subjected to low-flow ischemia, trimetazidine resulted in a 210% increase in glucose oxidation rates. In both aerobic and ischemic hearts, glycolytic rates were unaltered by trimetazidine. The effects of trimetazidine on glucose oxidation were accompanied by a 37% increase in the active form of pyruvate dehydrogenase, the rate-limiting enzyme for glucose oxidation. No effect of trimetazidine was observed on glycolysis, glucose oxidation, fatty acid oxidation, or active pyruvate dehydrogenase when palmitate was substituted with 0.8 mmol/L octanoate or 1.6 mmol/L butyrate, suggesting that trimetazidine directly inhibits long-chain fatty acid oxidation. This reduction in fatty acid oxidation was accompanied by a significant decrease in the activity of the long-chain isoform of the last enzyme involved in fatty acid ß-oxidation, 3-ketoacyl coenzyme A (CoA) thiolase activity (IC50 of 75 nmol/L). In contrast, concentrations of trimetazidine in excess of 10 and 100 µmol/L were needed to inhibit the medium- and short-chain forms of 3-ketoacyl CoA thiolase, respectively. Previous studies have shown that inhibition of fatty acid oxidation and stimulation of glucose oxidation can protect the ischemic heart. Therefore, our data suggest that the antianginal effects of trimetazidine may occur because of an inhibition of long-chain 3-ketoacyl CoA thiolase activity, which results in a reduction in fatty acid oxidation and a stimulation of glucose oxidation.
Key Words: glycolysis • mitochondria • trimetazidine
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Trimetazidine (1-[2,3,4-trimethoxybenzyl] piperazine dihydrochloride) is a clinically effective antianginal agent. In several double-blind trials, trimetazidine was shown to improve the ergometric exercise capacity and total work output of patients with effort angina,1 2 to reduce attack frequency and nitroglycerin requirement in patients with chronic stable angina,3 and to increase effort tolerance in angina patients.4 Multicenter trials of trimetazidine by a European collaborative working group have demonstrated that the antianginal efficacy of trimetazidine is equivalent to that of propranolol but does not reduce cardiac rate-pressure product or coronary blood flow.5 A similar lack of alteration of hemodynamic parameters with comparable antianginal effect was noted in comparison with nifedipine.6 In combination with diltiazem, additive antianginal effects were also observed.7 8 Trimetazidine has thus been considered unique among antianginal agents for its lack of vasodilator activity and has been termed a "cellular anti-ischemic agent (p 292)."9 It is presently clinically used throughout Europe and in >80 countries worldwide.
Despite these clinical successes, the understanding of trimetazidine’s mechanism of action remains incomplete. It is proposed to act by directly improving myocardial energy metabolism, resulting in cytoprotective effects in several models of myocardial ischemia.9 10 11 How could trimetazidine improve myocardial energy balance? Switching energy substrate preference from fatty acid oxidation to glucose oxidation is one possible means of improving cardiac function during ischemia and reperfusion, as well as improving both cardiac energetics and cardiac efficiency (see References 12 through 15 for reviews). A study by Fantini et al16 has shown in isolated rat heart mitochondria that trimetazidine has a potent inhibitory effect on palmitoylcarnitine oxidation, with no significant effect on pyruvate oxidation. This indirect evidence suggests that trimetazidine may act to inhibit fatty acid oxidation in the heart. Consistent with this, we have recently shown that another structurally similar piperazine derivative, ranolazine, also increases glucose oxidation in isolated working rat hearts, secondary to an inhibition of fatty acid oxidation.17
This indirect evidence suggests that trimetazidine may exert its antianginal effects by inhibiting fatty acid oxidation. High fatty acid oxidation rates are detrimental in the setting of ischemia and reperfusion because of an inhibition of glucose oxidation.18 19 This leads to an increase in proton production due to an uncoupling of glycolysis from glucose oxidation.19 20 This increase in proton production has the potential to accelerate sodium and calcium overload in the heart,21 resulting in an exacerbation of ischemic injury and a decrease in cardiac efficiency during reperfusion.14 15 19 20 Despite the observation that trimetazidine both improves cardiac energetics10 11 16 and attenuates proton and sodium accumulation during and after ischemia,22 it has not been directly determined what effect trimetazidine has on myocardial energy metabolism.
The purpose of this study was to determine whether trimetazidine exerts a direct effect on glycolysis, glucose oxidation, or fatty acid oxidation in the heart and to determine at what site trimetazidine alters energy metabolism in the heart. We demonstrate that trimetazidine potently inhibits long-chain 3-ketoacyl coenzyme A (CoA) thiolase in the heart, resulting in a reduction in fatty acid oxidation and an increase in glucose oxidation. This stimulation of glucose oxidation may explain the cardioprotective effect of trimetazidine seen in fatty acid–perfused ischemic rat hearts.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Heart Perfusions
Isolated working hearts from male Sprague-Dawley rats were subjected to a 60-minute aerobic perfusion period with a modified Krebs-Henseleit solution containing 5 mmol/L glucose; 100 µU/mL insulin; 3% BSA; and (in mmol/L) palmitate (16-carbon) 0.4, octanoate (8-carbon) 0.8, or butyrate (4-carbon) 1.6. Working hearts were used in these studies to approximate the metabolic demand of the heart seen in vivo.
An additional series of hearts perfused with 5 mmol/L glucose, 100 µU/mL insulin and 0.4 mmol/L palmitate were subjected to a 30-minute perfusion, after which they were switched to the Langendorff mode and subjected to a 60-minute period of low-flow ischemia (coronary flow=0.5 mL/min). Hearts were switched to the Langendorff mode during ischemia to obtain a constant coronary flow rate during ischemia.
Another series of hearts were perfused with Krebs-Henseleit perfusate containing 11 mmol/L glucose, 100 µU/mL insulin, and 1.2 mmol/L palmitate.
Spontaneously beating hearts were perfused at an 11.5–mm Hg left atrial preload and an 80–mm Hg aortic afterload. Heart rate, peak systolic pressure, developed pressure, cardiac output, aortic flow, coronary flow, cardiac work, and O2 consumption were measured as described previously.18 19 23
Trimetazidine, when present, was added 5 minutes into the perfusion period at the concentrations indicated in the tables and figures.
Glycolysis and glucose oxidation rates were determined simultaneously by the quantitative collection of 3H2O and 14CO2 produced by hearts perfused with buffer containing [5-3H/U-14]glucose.19 Rates of fatty acid oxidation were assessed during identical parallel heart perfusions using [1-14C]palmitate, [1-14C]octanoate, or [1-14C]butyrate. Palmitate, octanoate, or butyrate oxidation was determined by quantitatively collecting 14CO2 production as described above for glucose oxidation.
The rate of acetyl CoA production calculated from tricarboxylic acid (TCA)-cycle activity was as described previously.19 TCA-cycle efficiency was defined as the ratio of cardiac work to TCA-cycle acetyl CoA produced.
Biochemical Analysis
Analysis of active and total pyruvate
dehydrogenase (PDHa and PDHt, respectively) was as described
previously.23 24 Activities of long-chain, medium-chain,
and short-chain acyl CoA dehydrogenase in isolated rat heart
mitochondria were measured as described by Grimbert et
al.25 The long-, medium- and short-chain enoyl CoA
hydratase activities were assayed as described by Wanders et
al.26 Long-, medium, and short-chain
L-3-hydroxyacyl CoA dehydrogenase and 3-ketoacyl CoA
thiolase were measured in membrane and soluble mitochondrial fractions
as described by Venizelos et al.27
CoA esters were extracted from the frozen powdered heart tissue and quantified by high-performance liquid chromatography (HPLC).28 29 Myocardial AMP-activated protein kinase (AMPK), acetyl CoA carboxylase (ACC), malonyl CoA carboxylase, and triacylglycerols were measured as described previously.29 30 31
Statistical Analysis
All data are represented as the group mean±SEM.
Data were analyzed using the statistical program Instat.
One-way ANOVA was used to compare values among groups. A Tukey-Grammar
post hoc test was used to confirm intergroup differences.
P<0.05 was considered significant.
An expanded Materials and Methods section is available online at http://www.circresaha.org.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Effect of Trimetazidine on Cardiac Function
Table 1
online (see http://www.circresaha.org) shows the
effect of trimetazidine (1 µmol/L) on cardiac function in
isolated working rat hearts perfused in the presence of glucose as well
as palmitate, octanoate, or butyrate. Regardless of the type of fatty
acid substrate used, the presence of 1 µmol/L trimetazidine did
not cause any significant change in heart rate, peak systolic
pressure, developed pressure, cardiac output, or cardiac work. This
confirms earlier studies demonstrating that trimetazidine is not an
inotropic agent and demonstrates that any changes in energy substrate
metabolism in the heart are not occurring secondary to
effects of trimetazidine on cardiac function. Trimetazidine also did
not significantly alter O2 consumption in any of
the perfusion groups. Trimetazidine also did not have any effect on
coronary artery flow either, which argues against a primary
vasodilatory effect of this drug in the normoxic setting.
|
Effects of Trimetazidine on Energy Metabolism
The effect of trimetazidine on glucose and fatty acid utilization
rates in the presence of a physiological level of
long-chain fatty acid substrate (palmitate 0.4 mmol/L) is
demonstrated in Figure 1A through 1C.
Rates of glycolysis were unaltered by trimetazidine, although there was
a significant increase in glucose oxidation rates. In these hearts,
glycolytic rates were significantly greater than glucose oxidation
rates (Figure 1A and 1B). As a result, the selective increase in
glucose oxidation rates resulted in an improved coupling between
glycolysis and glucose oxidation. The increase in glucose oxidation
rates in the trimetazidine hearts was accompanied by a significant
decrease in palmitate oxidation rates (Figure 1C).
|
The effects of trimetazidine on glycolysis and glucose oxidation
in hearts subjected to low-flow ischemia (coronary
flow=0.5 mL/min) are shown in Figure 2.
During ischemia, glycolytic rates in control hearts were only
slightly lower than rates observed under aerobic conditions (Figure 1A
). However, as expected, a substantial decrease in glucose
oxidation rates was observed during ischemia (Figures 2 and 1B). Addition of trimetazidine had no effect on glycolytic
rates but did result in a significant increase in glucose oxidation
rates.
|
To determine whether the inhibitory effects of
trimetazidine on fatty acid oxidation were specific for long-chain
fatty acids, energy metabolism was also measured in hearts
perfused with octanoate (an 8-carbon fatty acid) (Figure 3) and butyrate (a 4-carbon fatty acid)
(Figure 4). In octanoate-perfused hearts,
trimetazidine did not have any significant effect on glycolysis,
glucose oxidation, or octanoate oxidation. Similarly, in the presence
of butyrate, trimetazidine was without effect on glycolysis, glucose
oxidation, or butyrate oxidation. This suggests that trimetazidine
specifically inhibits long-chain fatty acid oxidation and that the
stimulation of glucose oxidation does not occur in the presence of
shorter-chain fatty acids.
|
|
The effects of trimetazidine on cardiac work/TCA-cycle activity
were also calculated to determine whether trimetazidine alters
TCA-cycle efficiency in aerobically perfused hearts. As shown in Figure 1 online (see http://www.circresaha.org), no effect of trimetazidine
on cardiac work/TCA-cycle activity was observed regardless of whether
hearts were perfused with palmitate, octanoate, or butyrate. This
suggests that the decrease in palmitate oxidation by trimetazidine is
accompanied by a parallel increase in glucose oxidation.
We also determined whether trimetazidine was able to stimulate glucose
oxidation in hearts perfused with high levels of fatty acids (Table 1). As expected, rates of glucose
oxidation in untreated hearts were much lower in hearts perfused with
1.2 mmol/L palmitate (347±58 nmol · g dry
weight-1 ·
minute-1) compared with hearts perfused with
0.4 mmol/L palmitate (1889±119 nmol · g dry
weight-1 ·
minute-1) (Figure 1B). In contrast, rates
of glycolysis were not affected by fatty acid concentration, confirming
that fatty acids are much more potent inhibitors of glucose
oxidation than of glycolysis. As shown in Table 1, even with
glucose oxidation rates inhibited by high levels of fatty acids,
trimetazidine was able to significantly stimulate glucose oxidation. A
significant stimulation of glucose oxidation was observed in the
presence of 0.1 µmol/L trimetazidine. A maximal stimulation of
glucose oxidation was observed in the presence of 1 µmol/L
trimetazidine.
The heart contains a sizeable triacylglycerol pool
that can contribute as a source of fatty acids for ß-oxidation. We
therefore measured triacylglycerol levels in the
palmitate-, octanoate-, and butyrate-perfused hearts at the end of the
60-minute perfusion period. Trimetazidine had no effect on
triacylglycerol levels in the palmitate-perfused
hearts (145.3±15.6 versus 150.6±38.4 µmol fatty acid/g dry
weight, in control and trimetazidine-treated hearts, respectively;
P=NS). Under control conditions,
triacylglycerol levels in octanoate- and
butyrate-perfused hearts (88.1±10.2 and 99.2±6.3 µmol fatty
acid/g dry weight, respectively) were lower than levels seen in
palmitate-perfused hearts (P<0.05). The oxidation of
unlabeled fatty acids released from triacylglycerol
hydrolyzed from these groups would explain the slightly higher cardiac
work/TCA-cycle activity observed in the octanoate- and
butyrate-perfused hearts compared with the palmitate-perfused hearts
(Figure 1 online, see http://www.circresaha.org). However, similar to
the palmitate-perfused hearts, trimetazidine had no effect on
triacylglycerol levels in the octanoate- and
butyrate-perfused hearts (83.4±6.6 and 104.9±17.2 µmol fatty
acid/g dry weight, respectively; P=NS compared with the
appropriate control perfusion group).
Effects of Trimetazidine on Pyruvate Dehydrogenase (PDH)
Activity
PDH is the rate-limiting step for glucose oxidation and is
inhibited when fatty acid oxidation rates are high (see Reference
14 for review). We therefore measured PDH activity in
hearts perfused with 5 mmol/L glucose and 0.4 mmol/L
palmitate (Table 2). In control hearts,
the active unphosphorylated form of the enzyme (PDHa)
was 18% as active as PDHt. These values are expected in hearts
perfused with normal levels of fatty acids. In hearts perfused with
1 µmol/L trimetazidine, a significant increase in PDHa was
observed, with no difference in PDHt. As a result, a significant
increase in the active-to-total ratio was observed. In hearts perfused
with octanoate, in which no increase in glucose oxidation was observed,
no significant difference in the PDHa (4.12±0.48 and 5.16±0.56
µmol acetyl CoA · g dry weight-1
· minute-1, in control and
trimetazidine-treated hearts, respectively; n=10 in each group) or PDHt
was observed (23.9±2.1 and 22.4±2.6 µmol acetyl CoA · g
dry weight-1 ·
minute-1 in control and trimetazidine-treated
hearts, respectively; n=10 in each group).
|
To determine whether the effects of trimetazidine were due to direct
actions on PDH itself, a large concentration of trimetazidine (100
µmol/L) was added directly to the incubation medium used to measure
PDHa and PDHt. As shown in Table 2 online (see
http://www.circresaha.org), trimetazidine had no direct effect on
either PDHa or PDHt, suggesting that the stimulation of PDHa seen in
Table 2 online was an indirect effect on trimetazidine and not due to a
direct stimulation of PDHa activity.
Effect of Trimetazidine on Levels of Malonyl CoA and the Enzymes
That Control Malonyl CoA Levels
Malonyl CoA is a potent inhibitor of fatty acid
oxidation due to inhibition of carnitine palmitoyltransferase (CPT) 1,
the rate-limiting step in fatty acid oxidation. We therefore determined
what effect trimetazidine had on malonyl CoA levels, because
measurements of energy metabolism suggest that
trimetazidine may directly inhibit fatty acid oxidation. The effect of
trimetazidine on malonyl CoA levels was measured in hearts perfused
with palmitate, octanoate, or butyrate. As shown in Table 3 online (see
http://www.circresaha.org), trimetazidine had no effect on malonyl CoA
levels in any of these 3 perfusion groups.
|
Malonyl CoA in the heart is synthesized by ACC and degraded by malonyl CoA decarboxylase (MCD).31 We therefore determined what effect trimetazidine had on enzyme activity in the hearts perfused with palmitate, as well as what effect trimetazidine had directly on enzyme activity. Addition of trimetazidine to palmitate-perfused hearts did not result in any change in either ACC activity (8.23±0.4 and 6.43±0.35 nmol · mg protein-1 · minute-1 [P=NS] in control and trimetazidine-treated hearts, respectively; n=9 in each group). Trimetazidine also had no effect on citrate-stimulatable ACC activity. It also had no effect on MCD activity (8.01±0.46 and 6.87±0.29 µmol · mg protein-1 · minute-l [P=NS], in control and trimetazidine-treated hearts, respectively; n=9 in each group). Although the cellular location of MCD has yet to be established (ie, some is probably intramitochondrial), our data suggest that trimetazidine does not alter fatty acid oxidation by altering MCD activity. Because ACC is also inhibited by AMPK, we also determined what effect trimetazidine had on AMPK activity in the palmitate-perfused hearts. Similar to ACC and MCD, no significant effect of trimetazidine on AMPK activity was observed (852±111 and 1022±191 pmol · mg protein-1 · minute-l [P=NS] in control and trimetazidine-treated hearts, respectively, n=9 in each group).
Direct addition of 10 µmol/L trimetazidine to the incubation medium was also without effect on the activity of ACC, MCD, or AMPK (data not shown).
Effect of Trimetazidine on Myocardial CoA Ester Levels
The effects of trimetazidine on other measured short-chain CoA
esters in the palmitate-, octanoate-, and butyrate-perfused hearts are
also shown in Table 3 online (see http://www.circresaha.org). No effect
of trimetazidine was observed on any of the measured CoA esters. The
lack of effect on succinyl CoA levels suggests that, despite the
inhibition of fatty acid oxidation in palmitate-perfused hearts, the
supply of carbon for the TCA cycle was not compromised.
The effects of trimetazidine on levels of long-chain CoA, acetyl CoA, and free CoA are shown in Table 4 online (see http://www.circresaha.org). As expected, levels of long-chain acyl CoA were highest in hearts perfused with palmitate, compared with either octanoate- or butyrate-perfused hearts. However, trimetazidine did not affect long-chain acyl CoA levels in any perfusion group. Similarly, no effect of trimetazidine on acetyl CoA levels was observed in any of the perfusion groups. Trimetazidine did result in a significant increase in free CoA in hearts perfused with palmitate, which would be expected if trimetazidine directly inhibited long-chain fatty acid ß-oxidation. However, the ratio of acetyl CoA/CoA was not significantly affected by trimetazidine in any of the perfusion groups.
Effect of Trimetazidine on the Enzymes of Fatty Acid
ß-Oxidation
Because reduction of fatty acid oxidation by trimetazidine could
not be explained by alterations in malonyl CoA control of mitochondrial
fatty acid uptake, we directly measured the effects of trimetazidine on
the enzymes of mitochondrial fatty acid ß-oxidation. Table 3 summarizes the activities of long-,
medium- and short-chain isoforms of acyl CoA dehydrogenase, enoyl CoA
dehydrogenase, and L-3-hydroxyacyl CoA dehydrogenase
activity. The presence of 10 or 75 µmol/L trimetazidine did not
have any significant effect on any of the isoforms for the first 3
enzymes involved in mitochondrial fatty acid ß-oxidation.
Concentration effects of trimetazidine on enzyme activities were also
measured, which confirmed that trimetazidine did not alter the activity
of any of these enzymes (data not shown).
The effect of trimetazidine on the long-, medium, and short-chain
isoform of 3-ketoacyl CoA thiolase is shown in Figure 5. Trimetazidine caused a potent
inhibition of long-chain 3-ketoacyl CoA thiolase, with an
IC50 of 
75 nmol/L. In contrast, a
concentration of 10 µmol/L trimetazidine was necessary to
significantly inhibit the medium-chain 3-ketoacyl CoA thiolase, and
concentrations in excess of 100 µmol/L were necessary to inhibit
the short-chain 3-ketoacyl CoA thiolase. In these experiments,
4-pentenoic acid, a nonselective inhibitor of 3-ketoacyl
CoA thiolase, was used as a positive inhibitor control. As
expected, 4-pentenoic acid inhibited the enzyme activities of all 3
isoforms of 3-ketoacyl CoA thiolase.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Although the clinical efficacy of trimetazidine as an anti-ischemic agent is undisputed, its cellular mechanism of action has not been previously delineated. In this study, we demonstrate that trimetazidine directly inhibits fatty acid oxidation in the heart, secondary to an inhibition of mitochondrial long-chain 3-ketoacyl CoA thiolase. The selective inhibition of the long-chain 3-ketoacyl CoA thiolase is consistent with a specific inhibition by trimetazidine of long-chain fatty acid oxidation and not medium- or short-chain fatty acids. This inhibition of long-chain fatty acid oxidation is accompanied by an increase in PDH activity, resulting in a significant increase in glucose oxidation rates. The increase in glucose oxidation is seen regardless of whether hearts are perfused with low or high concentrations of fatty acids and is also observed in hearts subjected to low-flow ischemia. Furthermore, trimetazidine is without effect on glycolytic rates, which will improve the coupling between glycolysis and glucose oxidation and a decrease in proton production from glucose metabolism. Because increasing glucose oxidation and decreasing proton production from glucose metabolism is cardioprotective (see References 14 and 15 for reviews), we hypothesize that reduction in fatty acid oxidation is the mechanism by which trimetazidine exerts its antianginal effects. Our data also implicate inhibition of long-chain 3-ketoacyl CoA thiolase as the site of action for the beneficial anti-ischemic effects of trimetazidine. It also confirms that reduction in fatty acid oxidation is a novel approach to treating ischemic heart disease.
Trimetazidine and Myocardial Fatty Acid Oxidation
The demonstration that trimetazidine can inhibit fatty acid
oxidation in palmitate-perfused hearts is consistent with the
previous studies of Fantini et al16 using isolated
mitochondrial preparations. These authors demonstrated that
trimetazidine could markedly reduce in vitro mitochondrial respiratory
activity but that this effect is dependent on the substrate offered to
the mitochondria; ie, palmitoylcarnitine oxidation is markedly reduced,
but not that of pyruvate, glutamate, or citrate.16 This
suggests that trimetazidine is not inhibiting either TCA-cycle activity
or mitochondrial oxidative phosphorylation, but rather
is directly inhibiting fatty acid ß-oxidation. This is supported by
our data, in which we demonstrate that trimetazidine does not alter
overall oxygen consumption in aerobically perfused hearts (Table 1
online, see http://www.circresaha.org), nor does it alter TCA-cycle
activity or cardiac work/TCA-cycle activity (Figure 1 online, see
http://www.circresaha.org). Rather, the effects of trimetazidine are
associated with a switch in the source of acetyl CoA for the TCA cycle
from fatty acid ß-oxidation to glucose oxidation. This is not due to
a direct stimulation of PDH, but rather an indirect stimulation of PDH
secondary to a reduction in fatty acid oxidation. Because fatty acid
ß-oxidation rates are a key determinant of PDH
activity,32 trimetazidine reduction in fatty acid
oxidation was accompanied by an increase in glucose oxidation, with no
overall decrease in the levels of TCA-cycle intermediates (Tables 3 and
4 online, see http://www.circresaha.org).
Mitochondrial uptake of fatty acids is another important site at which
myocardial fatty acid oxidation can be inhibited. CPT 1 is an important
enzyme in this process and is potently inhibited by malonyl CoA.
Because long-chain fatty acid uptake by the mitochondria, and not
medium- or short-chain fatty acid uptake, is dependent on CPT 1, it is
possible that the effects of trimetazidine on fatty acid oxidation may
be occurring secondary to an inhibition of CPT 1 activity. However, we
believe this is unlikely for a number of reasons, as follows. (1)
Previous studies have shown that trimetazidine does not directly
inhibit CPT 1 activity.33 (2) Inhibition of mitochondrial
respiration of palmitoylcarnitine would not occur if trimetazidine were
acting at the level of CPT 1.16 (3) CPT 1
inhibitors result in a decrease in long-chain acyl CoA
levels, presumably because of a decrease in mitochondrial long-chain
acyl CoA levels.34 As shown in our studies, trimetazidine
did not lower long-chain acyl CoA levels (Table 3 online [see
http://www.circresaha.org]), which is consistent with a site
of inhibition lower in the fatty acid ß-oxidation pathway. (4)
Trimetazidine did not alter the levels of malonyl CoA under any
perfusion condition, nor did it alter the activity of any of the
enzymes involved in the regulation of malonyl CoA synthesis or
degradation (ACC, MCD, or AMPK).
Combined, these data suggest that trimetazidine inhibits fatty acid oxidation directly in the ß-oxidative pathway.
The ß-oxidation of fatty acids utilizes 4 enzymes, including acyl CoA
dehydrogenase, enoyl CoA hydratase, L-3-hydroxyacyl CoA
dehydrogenase, and 3-ketoacyl CoA thiolase. Each of these enzymes
exists as a number of different isoforms, with each isoform having a
different specificity for fatty acyl-chain length (see Reference
35 for review). This allows complete oxidation of
fatty acids as successive cycles shorten the fatty acyl esters. As
shown in Table 3, trimetazidine did not inhibit any isoform of
the first 3 ß-oxidative enzymes, but was a potent
inhibitor of long-chain 3-ketoacyl CoA thiolase (Figure 5), the enzyme catalyzing the last step in ß-oxidation. The
concentration of trimetazidine necessary to inhibit long-chain
3-ketoacyl CoA thiolase is consistent with the concentration of
trimetazidine necessary to stimulate glucose oxidation in hearts
perfused with high levels of fatty acids (Table 1) and is
compatible with the clinically relevant plasma concentrations seen in
patients taking trimetazidine for the treatment of
angina.36 Although trimetazidine also inhibited the
medium- and short-chain isoforms of 3-ketoacyl CoA thiolase, the
concentrations needed were much higher than clinically relevant
concentrations. The observation that trimetazidine was ineffective at
inhibiting either octanoate or butyrate oxidation is also
consistent with an inhibition of long-chain 3-ketoacyl CoA
thiolase, given that both of these substrates enter the ß-oxidative
pathway at a level beyond long-chain 3-ketoacyl CoA thiolase. The
selective increase in free CoA by trimetazidine in palmitate-perfused
hearts is also consistent with inhibition of long-chain
3-ketoacyl CoA thiolase.
In octanoate-perfused hearts, trimetazidine did result in a small, nonsignificant decrease in octanoate oxidation, as well as a small, nonsignificant increase in PDHa. A possible explanation for this may be that the long-chain 3-ketoacyl CoA thiolase may be metabolizing some of the octanoate. Although the long-chain 3-ketoacyl CoA thiolase prefers fatty acids of 10 carbons or greater in length, it can use 8-carbon–length fatty acids as a substrate (albeit with a lower affinity). Unfortunately, no study to date has clearly defined what proportion of medium-chain 3-ketoacyl CoAs are metabolized by the long- versus medium-chain 3-ketoacyl CoA thiolase in vivo. Therefore, it is possible that inhibition of the long-chain 3-ketoacyl CoA thiolase by trimetazidine could have some effect on overall octanoate oxidation rates (and therefore a minor effect on PDH activity).
Trimetazidine and Glucose Oxidation
Our data also show that stimulation of PDHa and glucose oxidation
by trimetazidine does not occur by a direct effect on the PDH complex.
This is because trimetazidine had no direct effect on PDHa, and in
octanoate-perfused hearts trimetazidine had no effect on PDH activity.
The PDH complex that activates and then translocates
activated pyruvate into the mitochondrial matrix in the form of
acetyl CoA is the rate-limiting step for glucose oxidation by the TCA
cycle. PDH activity itself is subject to various control mechanisms,
including PDH kinase–mediated phosphorylation, which
inactivates the enzyme, and PDH phosphatase–mediated
dephosphorylation, which restores the active
state.32 Flux of fatty acids through ß-oxidation is
closely linked to PDHa, because both reduced equivalents and
accumulation of acetyl CoA from ß-oxidation activate the
kinase and decrease PDHa. In contrast, inhibition of fatty acid
oxidation has the opposite effect of decreasing kinase activity,
increasing PDHa, and stimulating glucose oxidation rates. As a result,
trimetazidine reduction in fatty acid oxidation was accompanied by a
significant increase in glucose oxidation rates.
Trimetazidine and Cardioprotection During and After
Ischemia
Energy metabolism during ischemia and during
reperfusion is closely linked to cardiac function, presenting the
clinician an arena for possible intervention. Current approaches that
are used to manipulate myocardial energy metabolism involve
either stimulating glucose metabolism or inhibiting fatty
acid metabolism. Numerous experimental studies have
demonstrated that stimulation of glucose oxidation both during and
after ischemia can benefit the ischemic heart (see
References 14 and 15 for reviews). By
improving the coupling of glycolysis to glucose oxidation, proton
production is decreased, resulting in a decrease in tissue
acidosis and an improvement in cardiac efficiency. As a result,
selective stimulation of glucose oxidation by trimetazidine may explain
the anti-ischemic effects of this agent, possibly by increasing
the coupling between glycolysis and glucose oxidation, thereby
decreasing proton production.
We propose that trimetazidine acts by reducing fatty acid oxidation, thereby increasing glucose oxidation before and during the ischemic event. This altered metabolic balance will improve the capacity of the ischemic heart to balance the dramatic increase in glycolytic flux with an increase in glucose oxidation. This strategy has been demonstrated to be effective in experimental as well as clinical settings using agents such as dichloroacetate or ranolazine, which stimulate glucose oxidation in the hearts.14 15 17
In summary, we demonstrate that trimetazidine inhibits fatty acid oxidation secondary to an inhibition of long-chain 3-ketoacyl CoA thiolase, resulting in an increase in glucose oxidation. This results in an improved coupling of glycolysis with glucose oxidation, which has previously been shown to protect the ischemic heart. As a result, switching energy substrate preference from fatty acid oxidation to glucose oxidation may explain the antianginal properties of trimetazidine.
|
Acknowledgments |
|---|
This work was funded by a grant from the Institut De Recherches Internationales Servier. P.F.K. is Clinical Fellow of the Heart and Stroke Foundation of Canada and the Alberta Heritage Foundation for Medical Research. G.D.L. is a Heritage Medical Scientist.
Received December 2, 1999; accepted January 20, 2000.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Sellier P. The effects of trimetazidine on ergometric parameters in exercise-induced angina: controlled multicenter double blind versus placebo study. Arch Mal Coeur Vaiss. 1986;79:1331–1336.[Medline] [Order article via Infotrieve]
2. Sellier P, Audouin P, Payen B, Duong TC, Ourbak P. Ergometric effects of a single administration of trimetazidine. Presse Med. 1986;15:1771–1774.
3. Passeron J. Effectiveness of trimetazidine in stable effort angina due to chronic coronary insufficiency: a double-blind versus placebo study. Presse Med. 1986;15:1775–1778.
4. Gallet M. Clinical effectiveness of trimetazidine in stable effort angina: a double blind versus placebo controlled study. Presse Med. 1986;15:1779–1782.
5. Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P. Trimetazidine: a new concept in the treatment of angina: comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br J Clin Pharmacol. 1994;3:279–288.
6. Dalla-Volta S, Maraglino G, Della-Valentina P, Viena P, Desideri A. Comparison of trimetazidine with nifedipene in effort angina: a double-blind, crossover study. Cardiovasc Drugs Ther. 1990;4:853–859.
7. Levy S, Group of South of France Investigators. Combination therapy of trimetazidine with diltiazem in patients with coronary artery disease. Am J Cardiol. 1995;76:12B–16B.[Medline] [Order article via Infotrieve]
8.
Manchanda SC, Krishnaswani S. Combination treatment
with trimetazidine and diltiazem in stable angina pectoris.
Heart. 1997;78:353–357.
9. Harpey C, Clauser P, Labrid C, Freyria JL, Poirier JP. Trimetazidine, a cellular anti-ischemic agent. Cardiovasc Drug Rev. 1989;6:292–312.
10. Lavanchy N, Martin J, Rossi A. Anti-ischemic effects of trimetazidine: 31P NMR spectroscopy in the isolated rat heart. Arch Int Pharmacodyn Ther. 1987;286:97–110.[Medline] [Order article via Infotrieve]
11. Kay L, Finelli C, Aussedat J, Guarnieri C, Rossi A. Improvement of long term preservation of the isolated arrested rat heart by trimetazidine: effects of the energy state and mitochondrial function. Am J Cardiol. 1995;76:45B–49B.[Medline] [Order article via Infotrieve]
12. Opie LH. Metabolism of the heart in health and disease. Am Heart J. 1968;76:685–689.[Medline] [Order article via Infotrieve]
13. Taegetmeyer H. Energy metabolism in the heart: from basic concepts to clinical application. Curr Prob Cardiol. 1994;19:59–113.[Medline] [Order article via Infotrieve]
14. Lopaschuk GD, Belke DD, Gamble J, Itoi I, Schönekess BO. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta. 1994;1213:263–276.[Medline] [Order article via Infotrieve]
15.
Stanley WC, Lopaschuk GD, Hall JL, McCormack JG.
Regulation of myocardial carbohydrate metabolism under
normal and ischemic conditions: potential for pharmacological
interventions. Cardiovasc Res. 1997;33:243–257.
16. Fantini E, Demaison L, Sentex E, Grynberg A, Athias P. Some biochemical aspects of the protective effect of Trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol. 1994;26 949–958.
17.
McCormack JG, Barr RL, Wolff AA, Lopaschuk GD.
Ranolazine stimulates glucose oxidation in normoxic, ischemic
and reperfused ischemic rat hearts. Circulation. 1996;93:135–142.
18.
Lopaschuk GD, Wambolt RB, Barr RL. An imbalance between
glycolysis and glucose oxidation is a possible explanation for the
detrimental effects of high levels of fatty acids during aerobic
reperfusion of ischemic hearts. J Pharmacol Exp
Ther. 1993;264:135–144.
19.
Liu B, el Alaoui-Talibi Z, Clanachan AS, Schulz R,
Lopaschuk GD. Uncoupling of contractile function from mitochondrial TCA
cycle activity and MVO2 during reperfusion of
ischemic hearts. Am J Physiol. 1996;270:H72–H80.
20.
Liu B, Clanachan AS, Schulz R, Lopaschuk GD. Cardiac
efficiency is improved after ischemia by altering both the
source and fate of protons. Circ Res. 1996;79:940–948.
21. Pierce GN, Czubryt MP. The contribution of ionic imbalance to ischemia/reperfusion-induced injury. J Mol Cell Cardiol. 1995;27:53–63.[Medline] [Order article via Infotrieve]
22. El Banani H, Bernard M, Baetz D, Cabanes E, Cozzone P, Lucien A, Feuvray D. Changes in nuclear magnetic resonance study of the effects of TMZ on intracellular Na+ and pH during ischemia and reperfusion. J Mol Cell Cardiol.. 1999;31:A53. Abstract.
23.
Collins-Nakai RL, Noseworthy D, Lopaschuk GD.
Epinephrine increases ATP production in hearts by
preferentially increasing glucose metabolism. Am
J Physiol. 1994;267:H1862–H1871.
24. Constantin-Teodosiu D, Cederblad G, Hultman E. A sensitive radioisotopic assay of pyruvate dehydrogenase complex in human muscle tissue. Anal Biochem. 1991;198:347–351.[Medline] [Order article via Infotrieve]
25.
Grimbert S, Fisch C, Deschamps D, Berson A, Fromenty B,
Feldman G, Pessayre D. Effects of female sex hormones on mitochondria:
possible role in acute fatty liver of pregnancy. Am J
Physiol. 1995;268:G107–G115.
26. Wanders RJA, Ijlst L, Poggi F, Bonnefont JP, Munnich A, Brivet M, Rabier D, Saudubray JM. Human trifunctional protein deficiency: a new disorder of mitochondrial fatty acid ß-oxidation. Biochem Biophys Res Commun. 1992;188:1139–1145.[Medline] [Order article via Infotrieve]
27. Venizelos N, Ijlst L, Wanders RJA, Hagenfeldt L. ß-Oxidation enzymes in fibroblasts from patients with 3-hydroxydicarboxylic aciduria. Pediatr Res. 1994;36:111–114.[Medline] [Order article via Infotrieve]
28.
Saddik M, Gamble J, Witters LA, Lopaschuk GD. Acetyl
CoA carboxylase regulation of fatty acid oxidation in the heart.
J Biol Chem. 1993;268:25836–25845.
29.
Kudo N, Barr A, Barr R, Desai S, Lopaschuk GD. High
rates of fatty acid oxidation during reperfusion of ischemic
hearts are associated with a decrease in malonyl-CoA levels due to an
increase in 5'AMP-activated protein kinase inhibition of
acetyl-CoA carboxylase. J Biol Chem. 1995;270:17513–17520.
30. Hardie DG, Salt IP, Hawley SA, Davies SP. AMP-activated protein kinase: an ultrasensitive system for monitoring cellular energy charge. Biochem J. 1999;338:717–722.
31.
Dyck JRB, Barr AJ, Barr RL, Kolattukudy PE,
Lopaschuk GD. Characterization of cardiac malonyl CoA decarboxylase and
its putative role in regulating fatty acid oxidation. Am J
Physiol. 1998;275:H2122–H2129.
32. Randle PJ, Hales CN, Garland PB, Newsholme EA. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetic mellitus. Lancet. 1963;i:785–789.
33. Willoughby SR, Chirkov YY, Kennedy JA, Murphy GA, Chirkova LP, Horowitz JD. Inhibition of long-chain fatty acid metabolism does not effect platelet aggregation responses. Eur J Pharmacol. 1998;356:207–213.[Medline] [Order article via Infotrieve]
34.
Lopaschuk GD, Spafford MA, Davies NJ, Wall SR. Glucose
and palmitate oxidation in isolated working rat hearts reperfused
following a period of transient global ischemia. Circ
Res. 1989;66:546–553.
35. Schulz H. Beta oxidation of fatty acids. Biochim Biophys Acta. 1991;1081:109–120.[Medline] [Order article via Infotrieve]
36. Sellier P, Audouin P, Payen B, Corona P, Duong TC, Ourbak P. Acute effects of trimetazidine evaluated by exercise testing. Eur J Clin Pharmacol.. 1987;33:205–207.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  G. Zemljic, M. Bunc, and B. Vrtovec Trimetazidine Shortens QTc Interval in Patients With Ischemic Heart Failure Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2010; 15(1): 31 - 36. [Abstract] [PDF]
|
|
|
|
 |
|
 G. D. Lopaschuk, J. R. Ussher, C. D. L. Folmes, J. S. Jaswal, and W. C. Stanley Myocardial Fatty Acid Metabolism in Health and Disease Physiol Rev, January 1, 2010; 90(1): 207 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Wisel, M. Khan, M. L. Kuppusamy, I. K. Mohan, S. M. Chacko, B. K. Rivera, B. C. Sun, K. Hideg, and P. Kuppusamy Pharmacological Preconditioning of Mesenchymal Stem Cells with Trimetazidine (1-[2,3,4-Trimethoxybenzyl]piperazine) Protects Hypoxic Cells against Oxidative Stress and Enhances Recovery of Myocardial Function in Infarcted Heart through Bcl-2 Expression J. Pharmacol. Exp. Ther., May 1, 2009; 329(2): 543 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tuunanen, E. Engblom, A. Naum, K. Nagren, M. Scheinin, B. Hesse, K.E. Juhani Airaksinen, P. Nuutila, P. Iozzo, H. Ukkonen, et al. Trimetazidine, a Metabolic Modulator, Has Cardiac and Extracardiac Benefits in Idiopathic Dilated Cardiomyopathy Circulation, September 16, 2008; 118(12): 1250 - 1258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sajapitak, K. Iwata, M. Shahab, Y. Uenoyama, S. Yamada, M. Kinoshita, F. Y. Bari, H. I'Anson, H. Tsukamura, and K.-i. Maeda Central Lipoprivation-Induced Suppression of Luteinizing Hormone Pulses Is Mediated by Paraventricular Catecholaminergic Inputs in Female Rats Endocrinology, June 1, 2008; 149(6): 3016 - 3024. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Doenst, H. Bugger, M. Schwarzer, G. Faerber, M. A. Borger, and F. W. Mohr Three good reasons for heart surgeons to understand cardiac metabolism Eur. J. Cardiothorac. Surg., May 1, 2008; 33(5): 862 - 871. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Wu, F. Yang, K. C. Vinnakota, and D. A. Beard Computer Modeling of Mitochondrial Tricarboxylic Acid Cycle, Oxidative Phosphorylation, Metabolite Transport, and Electrophysiology J. Biol. Chem., August 24, 2007; 282(34): 24525 - 24537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Lopaschuk, C. D.L. Folmes, and W. C. Stanley Cardiac Energy Metabolism in Obesity Circ. Res., August 17, 2007; 101(4): 335 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. O Onbasili, Y. Yeniceriglu, P. Agaoglu, A. Karul, T. Tekten, H. Akar, and G. Discigil Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures Heart, June 1, 2007; 93(6): 698 - 702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Bonello, P. Sbragia, N. Amabile, O. Com, S. V Pierre, S. Levy, and F. Paganelli Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention Heart, June 1, 2007; 93(6): 703 - 707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Belardinelli, M. Solenghi, L. Volpe, and A. Purcaro Trimetazidine improves endothelial dysfunction in chronic heart failure: an antioxidant effect Eur. Heart J., May 1, 2007; 28(9): 1102 - 1108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Jayle, F. Favreau, K. Zhang, C. Doucet, J. M. Goujon, W. Hebrard, M. Carretier, M. Eugene, G. Mauco, J. P. Tillement, et al. Comparison of protective effects of trimetazidine against experimental warm ischemia of different durations: early and long-term effects in a pig kidney model Am J Physiol Renal Physiol, March 1, 2007; 292(3): F1082 - F1093. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gambert, C. Helies-Toussaint, and A. Grynberg Extracellular glycerol regulates the cardiac energy balance in a working rat heart model Am J Physiol Heart Circ Physiol, March 1, 2007; 292(3): H1600 - H1606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Horowitz and J. A. Kennedy Time to Address the Cardiac Metabolic "Triple Whammy": Ischemic Heart Failure in Diabetic Patients J. Am. Coll. Cardiol., December 5, 2006; 48(11): 2232 - 2234. [Full Text] [PDF]
|
|
|
|
|
|
G. Fragasso, A. Palloshi, P. Puccetti, C. Silipigni, A. Rossodivita, M. Pala, G. Calori, O. Alfieri, and A. Margonato A Randomized Clinical Trial of Trimetazidine, a Partial Free Fatty Acid Oxidation Inhibitor, in Patients With Heart Failure J. Am. Coll. Cardiol., September 5, 2006; 48(5): 992 - 998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. K. Kutala, M. Khan, R. Mandal, L. P. Ganesan, S. Tridandapani, T. Kalai, K. Hideg, and P. Kuppusamy Attenuation of Myocardial Ischemia-Reperfusion Injury by Trimetazidine Derivatives Functionalized with Antioxidant Properties J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 921 - 928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Meng, L. Feng, X.-J. Chen, D. Yang, and J.-N. Zhang Trimetazidine improved Ca2+ handling in isoprenalinemediated myocardial injury of rats Exp Physiol, May 1, 2006; 91(3): 591 - 601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Fragasso, G. Perseghin, F. De Cobelli, A. Esposito, A. Palloshi, G. Lattuada, P. Scifo, G. Calori, A. Del Maschio, and A. Margonato Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure Eur. Heart J., April 2, 2006; 27(8): 942 - 948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. D. Monti, E. Setola, G. Fragasso, R. P. Camisasca, P. Lucotti, E. Galluccio, A. Origgi, A. Margonato, and P. Piatti Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy Am J Physiol Endocrinol Metab, January 1, 2006; 290(1): E54 - E59. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Sambandam, D. Morabito, C. Wagg, B. N. Finck, D. P. Kelly, and G. D. Lopaschuk Chronic activation of PPAR{alpha} is detrimental to cardiac recovery after ischemia Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H87 - H95. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Parang, B. Singh, and R. Arora Metabolic Modulators for Chronic Cardiac Ischemia Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2005; 10(4): 217 - 223. [Abstract] [PDF]
|
|
|
|
|
|
W. C. Stanley, F. A. Recchia, and G. D. Lopaschuk Myocardial Substrate Metabolism in the Normal and Failing Heart Physiol Rev, July 1, 2005; 85(3): 1093 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Saeedi, M. Grist, R. B. Wambolt, A. Bescond-Jacquet, A. Lucien, and M. F. Allard Trimetazidine Normalizes Postischemic Function of Hypertrophied Rat Hearts J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 446 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Thiele, N. D. Price, T. D. Vo, and B. O. Palsson Candidate Metabolic Network States in Human Mitochondria: IMPACT OF DIABETES, ISCHEMIA, AND DIET J. Biol. Chem., March 25, 2005; 280(12): 11683 - 11695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E O'Meara and J J V McMurray Myocardial metabolic manipulation: a new therapeutic approach in heart failure? Heart, February 1, 2005; 91(2): 131 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P Di Napoli, A A Taccardi, and A Barsotti Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy Heart, February 1, 2005; 91(2): 161 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Hanley, S. Drose, U. Brandt, R. A. Lareau, A. L. Banerjee, D. K. Srivastava, L. J. Banaszak, J. J. Barycki, P. P. Van Veldhoven, and J. Daut 5-Hydroxydecanoate is metabolised in mitochondria and creates a rate-limiting bottleneck for {beta}-oxidation of fatty acids J. Physiol., January 15, 2005; 562(2): 307 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Vitale, M. Wajngaten, B. Sposato, O. Gebara, P. Rossini, M. Fini, M. Volterrani, and G. M.C. Rosano Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease Eur. Heart J., October 2, 2004; 25(20): 1814 - 1821. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Huss and D. P. Kelly Nuclear Receptor Signaling and Cardiac Energetics Circ. Res., September 17, 2004; 95(6): 568 - 578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Taegtmeyer Cardiac Metabolism as a Target for the Treatment of Heart Failure Circulation, August 24, 2004; 110(8): 894 - 896. [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Magner and D. Royston Heart failure Br. J. Anaesth., July 1, 2004; 93(1): 74 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R.B. Dyck, J.-F. Cheng, W. C. Stanley, R. Barr, M. P. Chandler, S. Brown, D. Wallace, T. Arrhenius, C. Harmon, G. Yang, et al. Malonyl Coenzyme A Decarboxylase Inhibition Protects the Ischemic Heart by Inhibiting Fatty Acid Oxidation and Stimulating Glucose Oxidation Circ. Res., May 14, 2004; 94(9): e78 - e84. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Lee, J. Horowitz, and M. Frenneaux Metabolic manipulation in ischaemic heart disease, a novel approach to treatment Eur. Heart J., April 2, 2004; 25(8): 634 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Khairallah, F. Labarthe, B. Bouchard, G. Danialou, B. J. Petrof, and C. Des Rosiers Profiling substrate fluxes in the isolated working mouse heart using 13C-labeled substrates: focusing on the origin and fate of pyruvate and citrate carbons Am J Physiol Heart Circ Physiol, April 1, 2004; 286(4): H1461 - H1470. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Opie Angina Pectoris: The Evolution of Concepts Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1_suppl): S3 - S9. [PDF]
|
|
|
|
|
|
U. Thadani Current Medical Management of Chronic Stable Angina Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1_suppl): S11 - S29. [Abstract] [PDF]
|
|
|
|
|
|
W. C. Stanley Myocardial Energy Metabolism During Ischemia and the Mechanisms of Metabolic Therapies Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1_suppl): S31 - S45. [Abstract] [PDF]
|
|
|
|
|
|
L. H. Opie Preconditioning and metabolic anti-ischaemic agents Eur. Heart J., October 2, 2003; 24(20): 1854 - 1856. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. MacInnes, D. A. Fairman, P. Binding, J. a. Rhodes, M. J. Wyatt, A. Phelan, P. S. Haddock, and E. H. Karran The Antianginal Agent Trimetazidine Does Not Exert Its Functional Benefit via Inhibition of Mitochondrial Long-Chain 3-Ketoacyl Coenzyme A Thiolase Circ. Res., August 8, 2003; 93 (3): e26 - e32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Lopaschuk, R. Barr, P. D. Thomas, and J. R.B. Dyck Beneficial Effects of Trimetazidine in Ex Vivo Working Ischemic Hearts Are Due to a Stimulation of Glucose Oxidation Secondary to Inhibition of Long-Chain 3-Ketoacyl Coenzyme A Thiolase Circ. Res., August 8, 2003; 93 (3): e33 - e37. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Chandler, P. N. Chavez, T. A. McElfresh, H. Huang, C. S. Harmon, and W. C. Stanley Partial inhibition of fatty acid oxidation increases regional contractile power and efficiency during demand-induced ischemia Cardiovasc Res, July 1, 2003; 59(1): 143 - 151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Lopaschuk and M. Marzilli Mode of Action of Trimetazidine and Other New Metabolic Agents in the Treatment of Ischemic Heart Disease Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2003; 7(1): 91 - 96. [PDF]
|
|
|
|
 |
|
 D. Tallarico, V. Rizzo, F. di Maio, F. Petretto, G. Bianco, G. Placanica, M. Marziali, V. Paravati, N. Gueli, F. Meloni, et al. Myocardial Cytoprotection by Trimetazidine Against Anthracycline-Induced Cardiotoxicity in Anticancer Chemotherapy Angiology, March 1, 2003; 54(2): 219 - 227. [Abstract] [PDF]
|
|
|
|
|
|
I. Tabbi-Anneni, C. Helies-Toussaint, D. Morin, A. Bescond-Jacquet, A. Lucien, and A. Grynberg Prevention of Heart Failure in Rats by Trimetazidine Treatment: A Consequence of Accelerated Phospholipid Turnover? J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1003 - 1009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ferrara, G. Guardigli, and R. Ferrari Myocardial metabolism: the diabetic heart Eur. Heart J. Suppl., January 1, 2003; 5(suppl_B): B15 - B18. [Abstract] [PDF]
|
|
|
|
|
|
M. Frenneaux New tricks for an old drug Eur. Heart J., December 2, 2002; 23(24): 1898 - 1899. [PDF]
|
|
|
|
|
|
R. K. Kudej, L. T. White, A. B. Kudej, S. F. Vatner, and E. D. Lewandowski Brief Increase in Carbohydrate Oxidation After Reperfusion Reverses Myocardial Stunning in Conscious Pigs Circulation, November 26, 2002; 106(22): 2836 - 2841. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Taegtmeyer, D. M. Cohen, M. Allard, R. Brownsey, and G. Lopaschuk Overestimating glycolysis in rat heart Am J Physiol Endocrinol Metab, November 1, 2002; 283(5): E1102 - E1104. [Full Text] [PDF]
|
|
|
|
|
|
R. Liao, M. Jain, L. Cui, J. D'Agostino, F. Aiello, I. Luptak, S. Ngoy, R. M. Mortensen, and R. Tian Cardiac-Specific Overexpression of GLUT1 Prevents the Development of Heart Failure Attributable to Pressure Overload in Mice Circulation, October 15, 2002; 106(16): 2125 - 2131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. Rottman, D. Bracy, C. Malabanan, Z. Yue, J. Clanton, and D. H. Wasserman Contrasting effects of exercise and NOS inhibition on tissue-specific fatty acid and glucose uptake in mice Am J Physiol Endocrinol Metab, July 1, 2002; 283(1): E116 - E123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Fragasso, P. M. Piatti, L. Monti, A. Palloshi, C. Lu, G. Valsecchi, E. Setola, G. Calori, G. Pozza, A. Margonato, et al. Acute effects of heparin administration on the ischemic threshold of patients with coronary artery disease: Evaluation of the protective role of the metabolic modulator trimetazidine J. Am. Coll. Cardiol., February 6, 2002; 39(3): 413 - 419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. D. Michelakis, M. S. McMurtry, X.-C. Wu, J. R.B. Dyck, R. Moudgil, T. A. Hopkins, G. D. Lopaschuk, L. Puttagunta, R. Waite, and S. L. Archer Dichloroacetate, a Metabolic Modulator, Prevents and Reverses Chronic Hypoxic Pulmonary Hypertension in Rats: Role of Increased Expression and Activity of Voltage-Gated Potassium Channels Circulation, January 15, 2002; 105(2): 244 - 250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Szwed, Z. Sadowski, W. Elikowski, A. Koronkiewicz, A. Mamcarz, W. Orszulak, E. Skibinska, K. Szymczak, J. Swiatek, and M. Winter Combination treatment in stable effort angina using trimetazidine and metoprolol. Results of a randomized, double-blind, multicentre study (TRIMPOL II) Eur. Heart J., December 2, 2001; 22(24): 2267 - 2274. [Abstract] [PDF]
|
|
|
|
|
|
D.V. Cokkinos Can metabolic manipulation reverse myocardial dysfunction? Eur. Heart J., December 1, 2001; 22(23): 2138 - 2139. [PDF]
|
|
|
|
|
|
R. Belardinelli and A. Purcaro Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy Eur. Heart J., December 1, 2001; 22(23): 2164 - 2170. [Abstract] [PDF]
|
|
|
|
|
|
Y. Iwado, K. Mizushige, K. Manabe, Y. Wada, I. Kondo, K. Ohmori, and M. Kohno Suppression of Fatty Acid Metabolism After Exercise Stress in Patients with No Electrocardiographic ST Segment Shift During Balloon Angioplasty Angiology, December 1, 2001; 52(12): 841 - 849. [Abstract] [PDF]
|
|
|
|
|
|
N. Rosenblatt-Velin, C. Montessuit, I. Papageorgiou, J. Terrand, and R. Lerch Postinfarction heart failure in rats is associated with upregulation of GLUT-1 and downregulation of genes of fatty acid metabolism Cardiovasc Res, December 1, 2001; 52(3): 407 - 416. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.C. Stanley Changes in cardiac metabolism: a critical step from stable angina to ischaemic cardiomyopathy Eur. Heart J. Suppl., November 1, 2001; 3(suppl_O): O2 - O7. [Abstract] [PDF]
|
|
|
|
|
|
M. Marzilli Trimetazidine: a metabolic agent for the treatment of stable angina Eur. Heart J. Suppl., November 1, 2001; 3(suppl_O): O12 - O15. [Abstract] [PDF]
|
|
|
|
|
|
S.L. Chierchia Trimetazidine and left ventricular ischaemic dysfunction: an overview of clinical evidence Eur. Heart J. Suppl., November 1, 2001; 3(suppl_O): O16 - O20. [Abstract] [PDF]
|
|
|
|
|
|
N. Danchin Recent advances in cardioprotection during myocardial revascularization procedures: benefit of a metabolic intervention Eur. Heart J. Suppl., November 1, 2001; 3(suppl_O): O21 - O25. [Abstract] [PDF]
|
|
|
|
|
|
L. D. Monti, S. Allibardi, P. M. Piatti, G. Valsecchi, S. Costa, G. Pozza, S. Chierchia, and M. Samaja Triglycerides impair postischemic recovery in isolated hearts: roles of endothelin-1 and trimetazidine Am J Physiol Heart Circ Physiol, September 1, 2001; 281(3): H1122 - H1130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Szwed Comments on EMIP-FR study's editorial Eur. Heart J., August 1, 2001; 22(15): 1359 - 1359. [Abstract] [PDF]
|
|
|
|
|
|
M. Marzilli and M. Mariani About EMIP-FR and reperfusion damage in AMI: a comment to the comment Eur. Heart J., June 1, 2001; 22(11): 973 - 975. [PDF]
|
|
|
|
|
|
A. Grynberg The EMIP-FR Study: the evolution of scientific background as a non-controlled parameter Eur. Heart J., June 1, 2001; 22(11): 975 - 977. [PDF]
|
|
|
|
|
|
G.D. Lopaschuk Trimetazidine in AMI Eur. Heart J., June 1, 2001; 22(11): 977 - 978. [PDF]
|
|
|
|
|
|
M. Taniguchi, C. Wilson, C. A. Hunter, D. J. Pehowich, A. S. Clanachan, and G. D. Lopaschuk Dichloroacetate improves cardiac efficiency after ischemia independent of changes in mitochondrial proton leak Am J Physiol Heart Circ Physiol, April 1, 2001; 280(4): H1762 - H1769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Taegtmeyer Metabolism--the lost child of cardiology J. Am. Coll. Cardiol., October 1, 2000; 36(4): 1386 - 1388. [Full Text] [PDF]
|
|
|
|
|
|
H. R. Cross Trimetazidine: a novel protective role via maintenance of Na+/K+-ATPase activity? Cardiovasc Res, September 1, 2000; 47(4): 637 - 639. [Full Text] [PDF]
|
|
|
|
|
|
H. El Banani, M. Bernard, D. Baetz, E. Cabanes, P. Cozzone, A. Lucien, and D. Feuvray Changes in intracellular sodium and pH during ischaemia-reperfusion are attenuated by trimetazidine: Comparison between low- and zero-flow ischaemia Cardiovasc Res, September 1, 2000; 47(4): 688 - 696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. D. Lewandowski Metabolic Mechanisms Associated With Antianginal Therapy Circ. Res., March 17, 2000; 86(5): 487 - 489. [Full Text] [PDF]
|
|
|
|
|
|
H. S. Leong, M. Grist, H. Parsons, R. B. Wambolt, G. D. Lopaschuk, R. Brownsey, and M. F. Allard Accelerated rates of glycolysis in the hypertrophied heart: are they a methodological artifact? Am J Physiol Endocrinol Metab, May 1, 2002; 282(5): E1039 - E1045. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Chandler, H. Huang, T. A. McElfresh, and W. C. Stanley Increased nonoxidative glycolysis despite continued fatty acid uptake during demand-induced myocardial ischemia Am J Physiol Heart Circ Physiol, May 1, 2002; 282(5): H1871 - H1878. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||